Answer
Co-administration with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89%.
Sources for this answer
- Kalydeco 150 mg film-coated tabletsVertex Pharmaceuticals (Europe) Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 35Document updated
Sources checked